The SA Journal Diabetes & Vascular Disease Vol 14 No 1 (July 2017)

39 / 44

SA JOURNAL OF DIABETES & VASCULAR DISEASE RESEARCH ARTICLE
VOLUME 14 NUMBER 1 • JULY 2017 37
subjects may be risky, especially in those with high glucose levels.
We plan in future to compare homomocysteine levels between
participants with and without the metabolic syndrome.
Acknowledgements
We thank the Tshwane University of Technology and the University
of Limpopo (Turfloop campus) for financial assistance.
References
1. Shaikh MK, Devrajani BR, Shaikh A, Shah SZA, Shaikh S, Singh D. Plasma
homocysteine level in patients with diabetes mellitus, World App Sc J 2012;
16(9): 1269–1273.
2. Akalin A, Alatas O, Colak O. Relation of plasma homocysteine levels to
atherosclerotic vascular disease and inflammation markers in type 2 diabetic
patients. Eur J Endocrinol 2008; 158; 47–52.
3. Babic N, Dervisevic A, Huskic J, Music, M. Coagulation factor VIII activity in
diabetes. Med Glas Ljek Kamore Zenicko-doboj Kantona 2011; 8(1): 134–139.
4. Creager MA, Luscher TF, Consentino F, Beckman JA. Diabetes and vascular
disease: Pathophysiology, clinical consequences and medical therapy. J Am Heart
Assoc 2003; 108: 1527–1532.
5. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR. Explaining the disease in
US death from coronary disease. New Engl J Med 2007; 356(23): 2388–2398.
6. Lowe GDO. Venous and arterial thrombosis: Epidemiology and risk factors at
various ages. Maturitas 2004; 47(4): 259–263.
7. Ntaios G, Savopoulos C, Grekas D, Hatzitolios A. Homocysteine metabolism and
causes of hyperhomocysteinaemia. Arch Cardio Dis 2009; 102(12): 847–854.
8. Robertson J, Iemolo F, Stabler SP, Allen RH, Spence JD. Vitamin B12, homocysteine
and carotid plaque in the era of folic acid fortification of enriched cereal grain
products. Can Med Assoc J 2005; 172(12): 1569–1573.
9. Guilliams TG. Homocysteine – a risk factor for vascular diseases. J Am Neutraceut
Assoc 2004; 7(1): 11–16.
10. Karatela RA, Sainani GS. Plasma homocysteine in obese, overweight and
hypertensive subjects in Mumbai. Indian Heart J 2009; 61(2): 156–159.
11. Hajer GR, van der Graaf Y, Olijhoek JK, Verhaar MC, Visseren FJ. Levels of
homocysteine are increased in metabolic syndrome patients but are not
associated with an increased cardiovascular risk, in contrast to patients without
the metabolic syndrome. Heart 2007; 93(2): 216–220.
12. Mishra PK, Tyagi N, Sen U, Joshua IG, Tyagi SC. Synergism in hyper-
homocysteinemia and diabetes: RHle of PPAR gamma and tempol. Cardiovasc
Diabetol 2010; 9(49): 1–8.
13. Schalinske KL. Interrelationship between diabetes and homocysteine metabolism:
Hormonal regulation of cystathionine beta-synthase. Nutr Rev 2003; 61(4): 136-
138
14. Elias AN, Eng S. Homocysteine concentrations in patients with diabetes mellitus –
relationship to microvascular and macrovascular disease. Diabetes Obesity Metab
2005; 117–121.
15. Vayá A, Carmona P, Badia N, Pérez R, Hernandez MA, Corella D. Homocysteine
levels and the metabolic syndrome in a Mediterranean population. Clin Hemorheol
Microcirc 2011; 47(1): 59–66.
16. Wedro BC. 2009 Blood pressure guidelines. Available at http://www. medicinenet.
com/script/main/art.asp?articlekey=83068. [Accessed: 21/09/2011].
17. Lim K, Steinberg G. Preeclampsia. 2010. Available from: http://emedicine.
[Accessed: 20/9/2011].
18. Sen U, Tyagi SC. Homocysteine and hypertension in diabetes: Does PPARγ have a
regulatory role? PPAR Res 2010, Article ID 806538, doi:10.1155/2010/806538.
19. Atif A, Rizvi MA, Tauheed S, Aamir I, Majeed F, Siddiqui K,et al. Serum homocysteine
concentrations in patients with hypertension. Pak J Physiol 2008; 4(1): 21–22.
20. Nabipour I, Ebrahim A, Jafari SM, Vahdat K, Assadi M, Movahed A, et al. The
metabolic syndrome is not associated with homocysteinemia: The Persian Gulf
healthy heart study. J Endocrinol Invest 2009; 32(5): 406–410.
21. Sundström J, Sullivan L, D’Agostino RB, Jacques PF, Selhub J, Rosenberg IH, et al.
Plasma homocysteine, hypertension incidence, and blood pressure tracking. The
Framingham heart study. Hypertension 2003; 42: 1100–1105.
22. Stehouwer CD, van Guldener C. Does homocysteine cause hypertension? Clin
Chem Lab Med 2003; 41(11): 1408–1411.
23. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al.
Lipoprotein management in patients with cardio-meta- bolic risk. J Am Coll of
Cardiol 2008; 31(4): 811–822.
24. Mahan LK, Escort-Stump S. Food, Nutrition and Diet Therapy, 11th edn.
Philadelphia: Elsevier 2007: 41, 46.
25. Mahan LK, Escort-Stump S. Food, Nutrition and Diet Therapy, 11th edn.
Philadelphia: Elsevier 2007: 864, 866, 872.
26. Nelson DL, Cox MM. Digestion, Mobilization, and Transport of Fats, 5th edn, New
York: WH Freeman and Co 2008: 346–347.
27. Barter P, Gotto AM, Larosa JC, Maroni J, Szarek M. HDL cholesterol, very low
levels of LDL cholesterol and cardiovascular events. N Engl J Med 2007; 357(13):
1301–1310.
28. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease
residual cardiovascular risk in managed care setting. J Manag Care Pharm 2008;
14(8): S3–S28.
29. Fahy E, Subramaniam S, Brown HA. A comprehensive classification system for
lipids. J Lipid Res 2005; 46(5): 839–862.
30. Obeid R, Herrmann W. Homocysteine and cholesterol: Guilt by association?
Stroke 2009; 40(7): e516.
31. Rippey FF. Thrombosis and Embolism. General Pathology, 1st edn, Johannesburg:
Witwatersrand University Press 2003: 103–109.
32. Malhotra R, Hoyo C, Ostbye T, Hughes G, Schwartz D, Tsolekile L, et al .
Deteminants of obesity in an urban township of South Africa. S Afr J Clin Nutr
2008; 21(4): 315–320.
33. Darvall KA, Sam RC, Silverman SH, Bradbury AW, Adam DJ. Obesity and
thrombosis. Eur J Vasc Endovasc Surg 2007; 33: 223–233.
34. Bodary PF, Randal J, Westrick BS, Wickenheiser KJ, Shen Y, Daniel T, et al . Effect
of leptin on arterial thrombosis following vascular injury in mice. J Am Med Ass
2002; 287(13): 1706–1709.
35. Goedecke JH, Jennings CL, Lambert EV. Obesity in South Africa. Chronic diseases
of lifestyle in South Africa since 1995–2005. Cape Town: South African Medical
Research Council, 2006: 65–79.
36. Sanlier N, Yabanci N. 2007. Relationship between body mass index, lipids and
homocysteine levels in university students. J Pak Med Assoc 2007; 57(10):
491–495.
37. EL Sammak M, Kandil M, EL-Hifni S, Hosni R, Ragab M. Elevated plasma
homocysteine is positively associated with age independent of C677T mutation
of the methylenetetrahydrofolate reductase gene in selected Egyptian subjects.
Int J Med Sci 2004; 1: 181–192.
TESAR 40 and 80 mg. Each tablet contains 40, 80 mg telmisartan respectively. S3 A45/7.1.3/0978, 0979.
NAM NS2 17/7.1.3/0023, 0024.For full prescribing information, refer to the package insert approved
by the Medicines Control Council, 11 June 2015. 1) Grassi G, et al.Cardioprotective effects of telmisartan
in uncomplicated and complicated hypertension. Journal of Renin-Angiotensin-Aldosterone System
2008;9(2):66-74. 2) Database of Medicine Prices (24 April 2017). Department of Health website.http://www.
- Accessed on 24 April 2017. 3) IMS MAT UNITS Dec 2016. TRC412/05/2017.
CUSTOMER CARE LINE 0860 PHARMA (742 762)
On guard
24 30
conveniently
30tablets
packed in
Telmisartan offers:
sustained
24hour
BP control1
protection
against the
early morning
BP surge1
cardiovascular
protection1
T E L M I S A R T A N
40 mg
80 mg esar
% 63
Up to
cost saving2
vs the originator
36
Up to
%
cost saving2
vs the market leader3